Sjögren's syndrome: A forty-year scientific journey

Journal of Autoimmunity

Volumn 51, Issue , 2014, Pages 1-9

  Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Sjogren's syndrome; SS

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CYCLOSPORIN A; EPITOPE; METHOTREXATE; MIZORIBINE; NANDROLONE DECANOATE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EPITHELIUM CELL; GENETIC RISK; HUMAN; LYMPHOMA; MINOR SALIVA GLAND; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SJOEGREN SYNDROME; STIMULATION; ANIMAL; AUTOIMMUNE DISEASES; COMPLICATION; HISTORY; IMMUNOLOGY; SJOGREN'S SYNDROME;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYMPHOMA; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84901284878     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.001     Document Type: Review

References (145)

1. Bunim J.J. Abroader spectrum of Sjogren's syndrome and its pathogenetic implications. Ann Rheum Dis 1961, 20:1-10.
2. Bloch K.J., Buchanan W.W., Wohl M.J., Bunim J.J. Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine 1965, 44:187-231.
3. Talal N. Sjogren's syndrome, lymphoproliferation, and renal tubular acidosis. Ann Intern Med 1971, 74:633-634.
4. Talal N. Sjogren's syndrome. Bull Rheum Dis 1966, 16:404-407.
5. Strand V., Talal N. Advances in the diagnosis and concept of Sjogren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis 1979, 30:1046-1052.
6. Talal N., Bunim J.J. The development of malignant lymphoma in the course of Sjoegren's syndrome. Am J Med 1964, 36:529-540.
7. Youinou P. Haralampos M. Moutsopoulos: a lifetime in autoimmunity. JAutoimmun 2010, 35:171-175.
8. Krimbas C. On Prof. Haralampos Moutsopoulos: the academic perspective. Autoimmun Rev 2004, 3:S3-S5.
9. Greenspan J.S., Daniels T.E., Talal N., Sylvester R.A. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974, 37:217-229.
10. Tarpley T.M., Anderson L.G., White C.L. Minor salivary gland involvement in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1974, 37:64-74.
11. Chisholm D.M., Mason D.K. Labial salivary gland biopsy in Sjogren's disease. JClin Pathol 1968, 21:656-660.
12. Talal N., Sylvester R.A., Daniels T.E., Greenspan J.S., Williams R.C. Tand B lymphocytes in peripheral blood and tissue lesions in Sjogren's syndrome. JClin Invest 1974, 53:180-189.
13. Chused T.M., Hardin J.A., Frank M.M., Green I. Identification of cells infiltrating the minor salivary glands in patients with Sjogren's syndrome. JImmunol 1974, 112:641-648.
14. Tzioufas A.G., Moutsopoulos H.M. Sjogren's syndrome. Rheumatology 1997, 32.1-32.12. J.H. Klippel, P.A. Dieppe (Eds.).
15. Moutsopoulos H. Sjogren's syndrome. Harrison's principles of internal medicine 1998, 1902. Mc Graw-Hill Company, Inc.
16. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. JAutoimmun 2010, 34:400-407.
17. Kapsogeorgou E.K., Christodoulou M.I., Panagiotakos D.B., Paikos S., Tassidou A., Tzioufas A.G., et al. Minor salivary gland inflammatory lesions in Sjogren syndrome: do they evolve?. J Rheumatol 2013, 40:1566-1571.
18. Boumba D., Skopouli F.N., Moutsopoulos H.M. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol 1995, 34:326-333.
19. Mitsias D.I., Tzioufas A.G., Veiopoulou C., Zintzaras E., Tassios I.K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 2002, 128:562-568.
20. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
21. Moutsopoulos H.M. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994, 72:162-165.
22. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. JAutoimmun 2013, 40:1566-1571.
23. Kapsogeorgou E.K., Abu-Helu R.F., Moutsopoulos H.M., Manoussakis M.N. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005, 52:1517-1521.
24. Casciola-Rosen L., Andrade F., Ulanet D., Wong W.B., Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. JExp Med 1999, 190:815-826.
25. Polihronis M., Tapinos N.I., Theocharis S.E., Economou A., Kittas C., Moutsopoulos H.M. Modes of epithelial cell death and repair in Sjogren's syndrome (SS). Clin Exp Immunol 1998, 114:485-490.
26. Mitsias D.I., Kapsogeorgou E.K., Moutsopoulos H.M. Sjogren's syndrome: why autoimmune epithelitis?. Oral Dis 2006, 12:523-532.
27. Triantafyllopoulou A., Moutsopoulos H.M. Autoimmunity and coxsackievirus infection in primary Sjogren's syndrome. Ann NY Acad Sci 2005, 1050:389-396.
28. Aslpaugh M.A., Tan E.M. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum 1976, 19:711-719.
29. Sestak A.L., Harley J.B., Yoshida S., Reichlin M. Lupus/Sjogren's autoantibody specificities in sera with paraproteins. JClin Invest 1987, 80:138-144.
30. Moutsopoulos H.M., Skopouli F.N., Sarras A.K., Tsampoulas C., Mavridis A.K., Constantopoulos S.H., et al. Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of d-penicillamine side effects. Ann Rheum Dis 1985, 44:215-219.
31. Routsias J.G., Tzioufas A.G., Moutsopoulos H.M. The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clinica chimica acta. Int J Clin Chem 2004, 340:1-25.
32. Routsias J.G., Touloupi E., Dotsika E., Moulia A., Tsikaris V., Sakarellos C., et al. Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Mol Med (Cambridge, Mass) 2002, 8:293-305.
33. Yiannaki E., Vlachoyiannopoulos P.G., Manoussakis M.N., Sakarellos C., Sakarellos-Daitsiotis M., Moutsopoulos H.M., et al. Study of antibody and T cell responses in rabbits immunized with synthetic human B cell epitope analogues of La (SSB) autoantigen. Clin Exp Immunol 2000, 121:551-556.
34. Staikou E.V., Routsias J.G., Makri A.A., Terzoglou A., Sakarellos-Daitsiotis M., Sakarellos C., et al. Calreticulin binds preferentially with B cell linear epitopes of Ro60kD autoantigen, enhancing recognition by anti-Ro60kD autoantibodies. Clin Exp Immunol 2003, 134:143-150.
35. Tzioufas A.G., Hantoumi I., Polihronis M., Xanthou G., Moutsopoulos H.M. Autoantibodies to La/SSB in patients with primary Sjogren's syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs). JAutoimmun 1999, 13:429-434.
36. Stea E.A., Routsias J.G., Samiotaki M., Panayotou G., Papalambros E., Moutsopoulos H.M., et al. Analysis of parotid glands of primary Sjogren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets. Clin Exp Immunol 2007, 147:81-89.
37. Terzoglou A.G., Routsias J.G., Moutsopoulos H.M., Tzioufas A.G. Post-translational modifications of the major linear epitope 169-190aa of Ro60kDa autoantigen alter the autoantibody binding. Clin Exp Immunol 2006, 146:60-65.
38. Routsias J.G., Dotsika E., Touloupi E., Papamattheou M., Sakarellos C., Sakarellos-Daitsiotis M., et al. Idiotype-anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289-308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. JAutoimmun 2003, 21:17-26.
39. Stea E.A., Routsias J.G., Clancy R.M., Buyon J.P., Moutsopoulos H.M., Tzioufas A.G. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006, 54:2228-2234.
40. Mavragani C.P., Moutsopoulos H.M. Sjogren's syndrome. Annu Rev Pathol Mech Dis 2014, 9:273-285.
41. Stiller C.R., Russell A.S., Dossetor J.B. Autoimmunity: present concepts. Ann Intern Med 1975, 82:405-410.
42. Moutsopoulos H.M., Boehm-Truitt M., Kassan S.S., Chused T.M. Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. JImmunol 1977, 119:1639-1644.
43. Gratwohl A.A., Moutsopoulos H.M., Chused T.M., Akizuki M., Wolf R.O., Sweet J.B., et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977, 87:703-706.
44. Chused T.M., Moutsopoulos H.M., Johnson A.H., Mann D.L. La-antigens in Sjögren's syndrome. Genetic control of autoimmune disease 1978, 57-59. Elsevier North Holland. N.R. Rose, P.E. Bigazzi, R.N.L. Warne (Eds.).
45. Taurog J.D., Moutsopoulos H.M., Rosenberg Y.J., Chused T.M., Steinberg A.D. CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. JExp Med 1979, 150:31-43.
46. Fye K.H., Terasaki P.I., Moutsopoulos H., Daniels T.E., Michalski J.P., Talal N. Association of Sjogren's syndrome with HLA-B8. Arthritis Rheum 1976, 19:883-886.
47. Chused T.M., Kassan S.S., Opelz G., Moutsopoulos H.M., Terasaki P.I. Sjogren's syndrome association with HLA-Dw3. New Engl J Med 1977, 296:895-897.
48. Moutsopoulos H.M., Mann D.L., Johnson A.H., Chused T.M. Genetic differences between primary and secondary sicca syndrome. New Engl J Med 1979, 301:761-763.
49. Mann D.L., Moutsopoulos H.M. HLA DR alloantigens in different subsets of patients with Sjogren's syndrome and in family members. Ann Rheum Dis 1983, 42:533-536.
50. Roitberg-Tambur A., Friedmann A., Safirman C., Markitziu A., Ben-Chetrit E., Rubinow A., et al. Molecular analysis of HLA class II genes in primary Sjogren's syndrome. A study of Israeli Jewish and Greek non-Jewish patients. Hum Immunol 1993, 36:235-242.
51. Moutsopoulos H.M., Chused T.M., Mann D.L., Klippel J.H., Fauci A.S., Frank M.M., et al. Sjogren's syndrome (Sicca syndrome): current issues. Ann Intern Med 1980, 92:212-226.
52. Ice J.A., Li H., Adrianto I., Lin P.C., Kelly J.A., Montgomery C.G., et al. Genetics of Sjogren's syndrome in the genome-wide association era. JAutoimmun 2012, 39:57-63.
53. Triantafyllopoulou A., Moutsopoulos H. Persistent viral infection in primary Sjogren's syndrome: review and perspectives. Clin Rev Allergy Immunol 2007, 32:210-214.
54. Kirou K.A., Mavragani C.P., Crow M.K. Activation of type I interferon in systemic lupus erythematosus. Expert Rev Clin Immunol 2007, 3:579-588.
55. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. JAutoimmun 2010, 35:225-231.
56. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., et al. Ahigh incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
57. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. New Engl J Med 1979, 301:5-8.
58. Mavragani C.P., Fragoulis G.E., Moutsopoulos H.M. Endocrine alterations in primary Sjogren's syndrome: an overview. JAutoimmun 2012, 39:354-358.
59. Mavragani C.P., Schini M., Gravani F., Kaltsas G., Moutsopoulos H.M. Brief report: adrenal autoimmunity in primary Sjogren's syndrome. Arthritis Rheum 2012, 64:4066-4071.
60. Karaiskos D., Mavragani C.P., Makaroni S., Zinzaras E., Voulgarelis M., Rabavilas A., et al. Stress, coping strategies and social support in patients with primary Sjogren's syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis 2009, 68:40-46.
61. Prause J.U., Manthorpe R., Oxholm P., Schiodt M. Definition and criteria for Sjogren's syndrome used by the contributors to the First International Seminar on Sjogren's syndrome-1986. Scand J Rheumatol 1986, 61:17-18.
62. Vitali C., Bombardieri S., Moutsopoulos H.M., Balestrieri G., Bencivelli W., Bernstein R.M., et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993, 36:340-347.
63. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
64. Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012, 64:475-487.
65. Simon B.G., Moutsopoulos H.M. Primary amyloidosis resembling sicca syndrome. Arthritis Rheum 1979, 22:932-934.
66. Reinertsen J.L., Schaefer E.J., Brewer H.B., Moutsopoulos H.M. Sicca-like syndrome in type V hyperlipoproteinemia. Arthritis Rheum 1980, 23:114-118.
67. Drosos A.A., Andonopoulos A.P., Costopoulos J.S., Papadimitriou C.S., Moutsopoulos H.M. Prevalence of primary Sjogren's syndrome in an elderly population. Br J Rheumatol 1988, 27:123-127.
68. Mavragani C.P., Skopouli F.N., Moutsopoulos H.M. Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome. JRheumatol 2009, 36:1626-1630.
69. Mavragani C.P., Fragoulis G.E., Rontogianni D., Kanariou M., Moutsopoulos H.M. Elevated IgG4 serum levels among primary Sjogren's syndrome patients: clinical, serological and histopathological associations. Arthritis Care Res 2013, 10.1002/acr.22216.
70. Zulman J., Jaffe R., Talal N. Evidence that the malignant lymphoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. New Engl J Med 1978, 299:1215-1220.
71. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89:888-892.
72. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
73. Moutsopoulos H.M., Balow J.E., Lawley T.J., Stahl N.I., Antonovych T.T., Chused T.M. Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978, 64:955-960.
74. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
75. Pavlidis N.A., Karsh J., Moutsopoulos H.M. The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol 1982, 9:685-690.
76. Tsokos M., Lazarou S.A., Moutsopoulos H.M. Vasculitis in primary Sjogren's syndrome. Histologic classification and clinical presentation. Am J Clin Pathol 1987, 88:26-31.
77. Tsampoulas C.G., Skopouli F.N., Sartoris D.J., Kaplan P., Kursunoglu S., Pineda C., et al. Hand radiographic changes in patients with primary and secondary Sjogren's syndrome. Scand J Rheumatol 1986, 15:333-339.
78. Skopouli F.N., Talal A., Galanopoulou V., Tsampoulas C.G., Drosos A.A., Moutsopoulos H.M. Raynaud's phenomenon in primary Sjogren's syndrome. JRheumatol 1990, 17:618-620.
79. Tsianos E.V., Moutsopoulos H.M. Sjogren's syndrome and the gut. Bailliere's Clin Rheumatol 1989, 3:357-370.
80. Skopouli F.N., Barbatis C., Moutsopoulos H.M. Liver involvement in primary Sjogren's syndrome. Br J Rheumatol 1994, 33:745-748.
81. Leroy J.P., Drosos A.A., Yiannopoulos D.I., Youinou P., Moutsopoulos H.M. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome. Arthritis Rheum 1990, 33:1579-1581.
82. Goules A., Masouridi S., Tzioufas A.G., Ioannidis J.P., Skopouli F.N., Moutsopoulos H.M. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Med (Baltimore) 2000, 79:241-249.
83. Goules A., Tatouli I., Moutsopoulos H.M., Tzioufas A.G. Clinically significant and biopsy-documented renal involvement in primary Sjogren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013, 2945-2953.
84. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999, 42:1765-1772.
85. Moutsopoulos H.M., Steinberg A.D., Fauci A.S., Lane H.C., Papadopoulos N.M. High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. JImmunol 1983, 130:2663-2665.
86. Moutsopoulos H.M., Costello R., Drosos A.A., Mavridis A.K., Papadopoulos N.M. Demonstration and identification of monoclonal proteins in the urine of patients with Sjogren's syndrome. Ann Rheum Dis 1985, 44:109-112.
87. Moutsopoulos H.M., Fauci A.S. Immunoregulation in Sjogren's syndrome: influence of serum factors on T-cell subpopulations. JClin Invest 1980, 65:519-528.
88. Fauci A.S., Moutsopoulos H.M. Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 1981, 24:577-583.
89. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996, 39:767-772.
90. Pavlidis N.A., Drosos A.A., Papadimitriou C., Talal N., Moutsopoulos H.M. Lymphoma in Sjogren's syndrome. Med Pediatr Oncol 1992, 20:279-283.
91. Tapinos N.I., Polihronis M., Moutsopoulos H.M. Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum 1999, 42:1466-1472.
92. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002, 46:741-747.
93. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. JAutoimmun 2014, 51:89-98.
94. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
95. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 2009, 88:284-293.
96. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011, 70:1363-1368.
97. Fragoulis G.E., Vakrakou A.G., Moutsopoulos H.M., Manoussakis M.N. Evidence of defective phagocytosis of apoptotic cells in patients with systemic lupus erythematosus(SLE) and primary Sjogren's syndrome (SS): correlation with clinical activity and serum aberrations. Ann Rheum Dis 2011, 70:676.
98. Fragoulis G.E., Moutsopoulos H.M., Manoussakis M.N. Decreased DNAase-I activity and the presence of anti-nuclear antibodies appear responsible for the increased phagocytosis of secondary necrotic material (SNEC) by phagocytes in primary Sjogren's syndrome(SS) and in systemic lupus erythematosus(SLE). Ann Rheum Dis 2010, 69:669.
99. Bloch K.J., Wohl M.J., Ship, Oglesby B.B., Bunim J.J. Sjogren's syndrome. 1. Serologic reactions in patients with Sjogren's syndrome with and without rheumatoid arthritis. Arthritis Rheum 1960, 3:287-297.
100. Moutsopoulos H.M., Webber B.L., Vlagopoulos T.P., Chused T.M., Decker J.L. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med 1979, 66:733-736.
101. Andonopoulos A.P., Drosos A.A., Skopouli F.N., Acritidis N.C., Moutsopoulos H.M. Secondary Sjogren's syndrome in rheumatoid arthritis. JRheumatol 1987, 14:1098-1103.
102. Andonopoulos A.P., Drosos A.A., Skopouli F.N., Moutsopoulos H.M. Sjogren's syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol 1989, 7:203-205.
103. Andonopoulos A.P., Skopouli F.N., Dimou G.S., Drosos A.A., Moutsopoulos H.M. Sjogren's syndrome in systemic lupus erythematosus. JRheumatol 1990, 17:201-204.
104. Tsianos E.V., Hoofnagle J.H., Fox P.C., Alspaugh M., Jones E.A., Schafer D.F., et al. Sjogren's syndrome in patients with primary biliary cirrhosis. Hepatology (Baltimore, Md) 1990, 11:730-734.
105. Skopouli F., Siouna-Fatourou H., Dimou G.S., Galanopoulou D., Papadimitriou C.S., Moutsopoulos H.M. Histologic lesion in labial salivary glands of patients with systemic lupus erythematosus. Oral Surg Oral Med Oral Pathol 1991, 72:208-212.
106. Drosos A.A., Andonopoulos A.P., Costopoulos J.S., Stavropoulos E.D., Papadimitriou C.S., Moutsopoulos H.M. Sjogren's syndrome in progressive systemic sclerosis. JRheumatol 1988, 15:965-968.
107. Drosos A.A., Andonopoulos A.P., Skopouli F.N. Keratoconjunctivitis sicca in rheumatoid arthritis. Clin Rheumatol 1988, 7:547-548.
108. Vlachoyiannopoulos P.G., Drosos A.A., Wiik A., Moutsopoulos H.M. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 1993, 32:297-301.
109. Bournia V.K., Diamanti K.D., Vlachoyiannopoulos P.G., Moutsopoulos H.M. Anticentromere antibody positive Sjogren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010, 12:R47.
110. Manoussakis M.N., Georgopoulou C., Zintzaras E., Spyropoulou M., Stavropoulou A., Skopouli F.N., et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004, 50:882-891.
111. Dafni U.G., Tzioufas A.G., Staikos P., Skopouli F.N., Moutsopoulos H.M. Prevalence of Sjogren's syndrome in a closed rural community. Ann Rheum Dis 1997, 56:521-525.
112. Adler S., Korner M., Forger F., Huscher D., Caversaccio M.D., Villiger P.M. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study. Arthritis Care Res 2013, 10.1002/acr.22052.
113. Mavragani C.P., Moutsopoulos N.M., Moutsopoulos H.M. The management of Sjogren's syndrome. Nat Clin Pract 2006, 2:252-261.
114. Mavragani C.P., Nezos A., Moutsopoulos H.M. New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 2013, 25:623-629.
115. Arentz G., Thurgood L.A., Lindop R., Chataway T.K., Gordon T.P. Secreted human Ro52 autoantibody proteomes express a restricted set of public clonotypes. JAutoimmun 2012, 39:466-470.
116. Agmon-Levin N., Kivity S., Tzioufas A.G., Lopez Hoyos M., Rozman B., Efes I., et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. JAutoimmun 2012, 39:234-239.
117. Cornec D., Devauchelle-Pensec V., Tobon G.J., Pers J.O., Jousse-Joulin S., Saraux A. Bcells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. JAutoimmun 2012, 39:161-167.
118. Amador-Patarroyo M.J., Arbelaez J.G., Mantilla R.D., Rodriguez-Rodriguez A., Cardenas-Roldan J., Pineda-Tamayo R., et al. Sjogren's syndrome at the crossroad of polyautoimmunity. JAutoimmun 2012, 39:199-205.
119. Singh N., Cohen P.L. The T cell in Sjogren's syndrome: force majeure, not spectateur. JAutoimmun 2012, 39:229-233.
120. Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles. JAutoimmun 2012, 39:15-26.
121. Seror R., Bottsma H., Bowman S.J., Dorner T., Gottenberg J.E., Mariette X., et al. Outcome measures for primary Sjogren's syndrome. JAutoimmun 2012, 39:97-102.
122. Tzioufas A.G., Vlachoyiannopoulos P.G. Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. JAutoimmun 2012, 39:1-3.
123. Guerrier T., Le Pottier L., Devauchelle V., Pers J.O., Jamin C., Youinou P. Role of toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. JAutoimmun 2012, 39:69-76.
124. Abdulahad W.H., Kroese F.G., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. JAutoimmun 2012, 39:103-111.
125. Takahashi H., Yamamoto M., Tabeya T., Suzuki C., Naishiro Y., Shinomura Y., et al. The immunobiology and clinical characteristics of IgG4 related diseases. JAutoimmun 2012, 39:93-96.
126. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. JAutoimmun 2012, 39:4-8.
127. Pavlakis P.P., Alexopoulos H., Kosmidis M.L., Mamali I., Moutsopoulos H.M., Tzioufas A.G., et al. Peripheral neuropathies in Sjogren's syndrome: a critical update on clinical features and pathogenetic mechanisms. JAutoimmun 2012, 39:27-33.
128. Manoussakis M.N., Tsinti M., Kapsogeorgou E.K., Moutsopoulos H.M. The salivary gland epithelial cells of patients with primary Sjogren's syndrome manifest significantly reduced responsiveness to 17β-estradiol. JAutoimmun 2012, 39:64-68.
129. Konttinen Y.T., Fuellen G., Bing Y., Porola P., Stegaev V., Trokovic N., et al. Sex steroids in Sjogren's syndrome. JAutoimmun 2012, 39:49-56.
130. Barrera M.J., Sanchez M., Aguilera S., Alliende C., Bahamondes V., Molina C., et al. Aberrant localization of fusion receptors involved in regulated exocytosis in salivary glands of Sjogren's syndrome patients is linked to ectopic mucin secretion. JAutoimmun 2012, 39:83-92.
131. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. JAutoimmun 2012, 282-291.
132. Baldini C., Talarico R., Tzioufas A.G., Bombardieri S. Classification criteria for Sjogren's syndrome: a critical review. JAutoimmun 2012, 39:9-14.
133. Selmi C., Meroni P.L., Gershwin M.E. Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. JAutoimmun 2012, 39:34-42.
134. + T cells from patients with primary Sjogren's syndrome. Arthritis Rheum 2013, 10.1002/art.38264.
135. Tobon G.J., Saraux A., Gottenberg J.E., Quartuccio L., Fabris M., Seror R., et al. Arthritis Rheum 2013, 3218-3227.
136. Lauvsnes M.B., Maroni S.S., Appenzeller S., Beyer M.K., Greve O.J., Kvaloy J.T., et al. Memory dysfunction in primary Sjogren's syndrome is associated with anti-NR2 antibodies. Arthritis Rheum 2013, 65:3209-3217.
137. Yin H., Cabrera-Perez J., Lai Z., Michael D., Weller M., Swaim W.D., et al. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjogren's syndrome and in mice. Arthritis Rheum 2013, 65:3228-3238.
138. See L.C., Kuo C.F., Chou I.J., Chiou M.J., Yu K.H. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin Arthritis Rheum 2013, 43:381-386.
139. Jin J.O., Kawai T., Cha S., Yu Q. Interleukin-7 enhances the Th1 response to promote the development of Sjogren's syndrome-like autoimmune exocrinopathy in mice. Arthritis Rheum 2013, 65:2132-2142.
140. Steinfeld S.D., Demols P., Salmon I., Kiss R., Appelboom T. Notice of retraction of two articles ("Infliximab in patients with primary Sjogren's syndrome: a pilot study" and "infliximab in patients with primary Sjogren's syndrome: one-year followup"). Arthritis Rheum 2013, 65:814.
141. Vitali C., Carotti M., Salaffi F. Is it the time to adopt salivary gland ultrasonography as an alternative diagnostic tool for the classification of patients with Sjogren's syndrome? Comment on the article by Cornec etal. Arthritis Rheum 2013, 65:1950.
142. St Clair E.W., Levesque M.C., Prak E.T., Vivino F.B., Alappatt C.J., Spychala M.E., et al. Autoimmunity centers of excellence. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013, 65:1097-1106.
143. Liao K.P., Kurreeman F., Li G., Duclos G., Murphy S., Guzman R., et al. Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis Rheum 2013, 65:571-581.
144. Bootsma H., Spijkervet F.K., Kroese F.G., Vissink A. Toward new classification criteria for Sjogren's syndrome?. Arthritis Rheum 2013, 65:21-23.
145. Cornec D., Jousse-Joulin S., Pers J.O., Marhadour T., Cochener B., Boisrame-Gastrin S., et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjogren's syndrome: toward new diagnostic criteria?. Arthritis Rheum 2013, 65:216-225.